PharmaVentures appoints senior director

Paul Phull will develop corporate advisory business

PharmaVentures, based in Oxford, UK, has hired Paul Phull as senior director to develop its corporate advisory business.

PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.

Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.

You may also like

Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing

BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany

The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

AstraZeneca resumes £300m UK investment as drug pricing and tariff landscape shifts

The Cambridge and Macclesfield programmes, paused amid NHS reimbursement disputes, are back on track following the US-UK pharmaceutical deal and a revised NHS rebate rate
Finance

BASF reports Q1 earnings as currency headwinds and Middle East conflict weigh on revenue

The German chemicals giant posted solid volume growth across most segments in the first quarter of 2026, but adverse currency effects eroded sales and pushed EBITDA before special items down
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Finance

Sun Pharma to acquire Organon in $11.75bn deal, expanding global manufacturing and biosimilars reach

The firm will acquire Organon in an all-cash $11.75bn transaction, creating a larger global pharma group with expanded manufacturing capacity, stronger women's health operations and a top-10 biosimilars position
Subscribe now